Float Short %

21.88

Margin Of Safety %

Put/Call OI Ratio

0.24

EPS Next Q Diff

-0.13

EPS Last/This Y

-1.6

EPS This/Next Y

-1.11

Price

32.4

Target Price

93.39

Analyst Recom

1.11

Performance Q

2.68

Relative Volume

1.05

Beta

0.75

Ticker: VKTX

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-09	VKTX	37.29	0.25	0.33	262138
2025-12-10	VKTX	37.53	0.24	0.17	265672
2025-12-11	VKTX	37.2	0.25	0.60	266712
2025-12-12	VKTX	37.04	0.25	0.20	270349
2025-12-15	VKTX	36.15	0.24	0.30	256584
2025-12-16	VKTX	35.71	0.24	0.16	262113
2025-12-17	VKTX	34.31	0.24	0.34	263726
2025-12-18	VKTX	33.96	0.25	0.17	265721
2025-12-19	VKTX	35.16	0.25	0.52	269130
2025-12-22	VKTX	35.36	0.24	0.24	244476
2025-12-23	VKTX	36.43	0.24	0.53	250762
2025-12-26	VKTX	37.21	0.24	0.15	254790
2025-12-29	VKTX	36.47	0.23	0.31	240273
2025-12-30	VKTX	35.33	0.24	0.38	242674
2025-12-31	VKTX	35.14	0.24	0.17	246336
2026-01-02	VKTX	35.43	0.24	0.23	247958
2026-01-05	VKTX	32.13	0.24	0.23	238221
2026-01-06	VKTX	32.28	0.24	0.22	247708
2026-01-07	VKTX	32.38	0.24	0.25	250189
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-09	VKTX	37.28	-180.3	-	-2.61
2025-12-10	VKTX	37.53	-180.3	-	-2.61
2025-12-11	VKTX	37.19	-180.3	-	-2.61
2025-12-12	VKTX	37.04	-180.3	-	-2.61
2025-12-15	VKTX	36.15	-180.3	-	-2.61
2025-12-16	VKTX	36.15	-180.3	-	-2.61
2025-12-17	VKTX	34.29	-180.3	-	-2.61
2025-12-18	VKTX	33.96	-180.3	-	-2.61
2025-12-19	VKTX	35.18	-180.3	-	-2.61
2025-12-22	VKTX	35.48	-180.3	-	-2.61
2025-12-23	VKTX	36.28	-180.3	-	-2.61
2025-12-26	VKTX	37.19	-180.3	-	-2.61
2025-12-29	VKTX	36.47	-180.3	-	-2.61
2025-12-30	VKTX	35.32	-180.3	-	-2.61
2025-12-31	VKTX	35.18	-180.3	-	-2.61
2026-01-02	VKTX	35.42	-180.3	-	-2.61
2026-01-05	VKTX	32.13	-180.3	-	-2.61
2026-01-06	VKTX	32.28	-180.3	-	-2.61
2026-01-07	VKTX	32.40	-180.3	-	-2.61
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-09	VKTX	-4.39	-2.84	22.57
2025-12-10	VKTX	-4.39	-2.84	20.93
2025-12-11	VKTX	-4.39	-2.84	20.93
2025-12-12	VKTX	-4.39	-2.84	20.93
2025-12-15	VKTX	-4.39	-2.95	20.93
2025-12-16	VKTX	-4.39	-2.95	20.93
2025-12-17	VKTX	-4.39	-2.95	20.93
2025-12-18	VKTX	-4.39	-2.95	20.93
2025-12-19	VKTX	-4.39	-2.95	20.93
2025-12-22	VKTX	-4.39	-3.18	20.93
2025-12-23	VKTX	-4.39	-3.18	20.93
2025-12-26	VKTX	-4.39	-3.18	21.88
2025-12-29	VKTX	-4.39	-3.18	21.88
2025-12-30	VKTX	-4.39	-3.18	21.88
2025-12-31	VKTX	-4.39	-3.18	21.88
2026-01-02	VKTX	-4.39	-3.18	21.88
2026-01-05	VKTX	-3.36	-3.19	21.88
2026-01-06	VKTX	-12.95	-3.19	21.88
2026-01-07	VKTX	-12.95	-3.19	21.88
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.81

Avg. EPS Est. Current Quarter

-0.9

Avg. EPS Est. Next Quarter

-0.94

Insider Transactions

-12.95

Institutional Transactions

-3.19

Beta

0.75

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

67.4

Max Drawdown 5-Year %

-78.9

Target Price

93.39

P/E

Forward P/E

PEG

P/S

P/B

5.11

P/Free Cash Flow

EPS

-2.12

Average EPS Est. Cur. Y

-2.61

EPS Next Y. (Est.)

-3.72

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

1.05

Return on Equity vs Sector %

-60.4

Return on Equity vs Industry %

-45.2

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Viking Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 50

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

stock quote shares VKTX – Viking Therapeutics, Inc. Stock Price stock today

news today VKTX – Viking Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch VKTX – Viking Therapeutics, Inc. yahoo finance google finance

stock history VKTX – Viking Therapeutics, Inc. invest stock market

stock prices VKTX premarket after hours

ticker VKTX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: VKTX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y